Perspective Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Perspective Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Perspective Therapeutics: 4 sponsored US clinical trials, 3 recruiting.
Perspective Therapeutics sponsors 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Melanoma (Skin), with 1 trials.
Upper-quartile sponsor footprint
Perspective Therapeutics sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
NCT05636618
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
NCT04904120
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
What is open in the Perspective Therapeutics pipeline
3 recruiting of 4 indexed (75% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Recurrent Melanoma (Skin) (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Perspective Therapeutics: open-pipeline peers nationwide
Peers matched on 4 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Perspective Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 75% open enrollment (± trial volume)
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
- Amydis · 75% recruiting · 4 trials
Related
What to do with this Perspective Therapeutics page
4 registered trials is a research-attention snapshot, not an endorsement of Perspective Therapeutics or any single study.
- 3 of Perspective Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Recurrent Melanoma (Skin) is the condition Perspective Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Melanoma (Skin) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Perspective Therapeutics pipeline card: 4 registered trials from official public datasets.Report a data error.